LAVA Therapeutics NV
lavatherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 6, 2025. Its latest SEC filing is a 15-12G from Dec 16, 2025.
10-Q for Q3 FY2025, filed Nov 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops cancer drug candidates made from bispecific antibodies that engage gamma delta T cells, for patients with blood cancers and solid tumors.
10-K for FY2024, filed Mar 28, 2025We are a clinical stage immuno-oncology company focused on developing our proprietary Gammabody® platform of bispecific gamma delta (gd) T…View ↗
Our Gammabody platform enables us to develop off-the-shelf bispecific T cell engagers that leverage the advantages of antibody-based…View ↗
We designed our Gammabody platform to be fully modular and compatible with existing anti-tumor antibodies to facilitate expedited discovery…View ↗
How Did They Make Money?
Pharmaceutical partners pay upfront to license drug candidates, make milestone payments when development or regulatory events occur, and may pay royalties when licensed drugs are sold; they also pay for agreed research, manufacturing, and supply work.
10-K for FY2024, filed Mar 28, 2025The Company does not currently have any commercial sales. The Company has entered into collaboration and licensing arrangements for…View ↗
In September 2022, the Company entered into a license agreement with Pfizer (formally Seagen Inc.) (“Pfizer”) to develop, manufacture, and…View ↗
Royalties are payable on a licensed-product-by-licensed product and country-by-country basis beginning with the first commercial sale of…View ↗
Under the Pfizer Agreement, the Company was also entitled to receive reimbursement of up to $6.5 million for certain agreed-to research…View ↗
$12M
-
10-K for FY2024, filed Mar 28, 2025
$12M ↗
Who Were Their Customers?
Pharmaceutical partners such as Pfizer and Johnson & Johnson license LAVA’s drug candidates and collaborate on development; the company also works with them on research, manufacturing, and supply activities.
10-K for FY2024, filed Mar 28, 2025In 2022, we entered into an exclusive license agreement with Pfizer (formerly Seagen Inc.) to develop, manufacture and commercialize EGFRd2…View ↗
In 2020, we entered into a research collaboration and license agreement with Johnson & Johnson (formerly Janssen) (“J&J”) for the discovery…View ↗
The Company does not currently have any commercial sales. The Company has entered into collaboration and licensing arrangements for…View ↗
Did Revenues Turn Into Profits?
No. It lost $25.1M in FY2024.
10-K for FY2024, filed Mar 28, 2025
−$29.7MView ↗
10-K for FY2024, filed Mar 28, 2025
−$25.1MView ↗
10-K for FY2024, filed Mar 28, 2025
−$19.6MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 6, 2025
−$7.2MView ↗
- ▼ −42% (Loss)
- vs −$12.3M in Q3 FY2024
-
Nov 21, 2025
XOMA’s tender offer closed and Nasdaq suspended LAVA shares
Shares tendered in the offer were accepted, and Nasdaq suspended trading of LAVA shares.
Sources
8-K, filed Nov 21, 2025
Following the Expiration Time, in accordance with the Purchase Agreement, Buyer commenced a subsequent offering period (the “Subsequent…View ↗
-
Nov 13, 2025
XOMA became LAVA’s majority owner
The closing changed control of LAVA, which became a majority-owned subsidiary of XOMA.
Sources
8-K, filed Nov 13, 2025
The information contained in the Introductory Note and Item 5.02 of this Current Report on Form 8-K is incorporated by reference into this…View ↗
-
Oct 17, 2025
LAVA and XOMA revised the tender-offer terms
Tendering shareholders would receive $1.04 per share plus a contingent value right, replacing the prior $1.16 to $1.24 range.
Sources
8-K, filed Oct 17, 2025
Pursuant to the Amendment, holders of common shares of the Company (the “Shares”, and such holders, the “Shareholders”) who tender their…View ↗
-
May 23, 2025
LAVA replaced PwC with KPMG as auditor
Sources
8-K, filed May 23, 2025
On May 20, 2025, the board of directors (the “Board”) of LAVA Therapeutics N.V. (the “Company”), upon the recommendation of the audit…View ↗
Pipeline focus
The earlier report included a prostate-cancer candidate; the latest report says that program was discontinued and centers its lead program on blood cancers.
20-F for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Mar 28, 2025We believe our Gammabody platform has the potential to develop treatments for patients with a wide variety of cancers, both as monotherapy…View ↗
Who Did They Compete With?
Competes with Acepodia, Adicet Bio, Biosion USA, Cytomed Therapeutics, Editas Medicine, Eureka Therapeutics, ImCheck Therapeutics, Immatics, IN8bio, Leucid Bio, PhosphoGam, Shattuck Labs, Sandhill Therapeutics, and TC BioPharm
10-K for FY2024, filed Mar 28, 2025Our competitors in the field of gd T cell targeting-therapy include Acepodia Inc., Adicet Bio, Inc., Biosion USA Inc., Cytomed…View ↗
Loading...
